glp-1 drugs and addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) substance use disorders: An emerging pharmacotherapeutic target GLP-1 drugs may fight addiction

In addition, glucagon may contribute, at least partly, to the development of diabetic cardiomyopathy, as antagonism of the GCGR reduced its incidence in a mouse model of diabetes over several months (Sharma et al

Those with more acute symptoms often landed up spending many months in hospital being given a range of bland diets or milk drips

Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C(10))

This over-production of endorphins improves your quality of sleep and is the basis of the other benefits listed below

edited and revised manuscript